E/C/F/TAF single tablet regimen in HIV-1 infected children and adolescents

Phase 3, open-label trial of elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (3 cohorts), sponsored by Gilead Sciences. Primary endpoints: Area Under the Concentration-Time Curve Over the Dosing Interval of Elvitegravir at 4 weeks, Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration of Tenofovir Alafenamide at 4 weeks and 3 more. Started May 2013; status: completed.